Institutional Biosafety Committee

Date / time 8/21/2025 10:00 AM | *Meeting called to order by:*

Dr. Andrew Hayhurst

Meeting adjourned at 10:25 AM

In Attendance by ZOOM

Member	Expertise	Present (Yes [Y]/ No[N])
Andrew Hayhurst, Ph.D.	Protein engineering, display systems, BoNT, BSL-2, 4 (chair)	Y
Tim Anderson, Ph.D.	Pathogen evolution, malaria & schistosome drug resistances	Y
Hsiang Ming (Anthony) Wang, Ph.D.	Director EHS, RO, alternate BSO, BSL-2, 3, 4	N
Marie-Claire Gauduin, Ph.D.	Recombinant virus vectors, NHP, HIV vaccines, retroviruses, BSL-2, 3	Y
Trent Peacock, Ph.D.	BSO, ARO, molecular diagnostics, BSL-2, 3, 4 (vice-chair)	N
Yan Xiang, Ph.D.	Mechanisms of poxvirus pathogenesis, (community member)	Y
Felicia Ponce	IACUC Manager	Y
Olena Shtanko, Ph.D.	Molecular virology, viral entry, pathogenesis, BSL-2, 3, 4	N
Davida Smyth, Ph.D.	Microbial epidemiology & genomics, (community member)	N
Luis Martinez Sobdrido, Ph.D.	Viral reverse genetics, attenuated vaccines, antivirals, BSL-2, 3, 4	Y
Diako Ebrahimi, Ph.D.	Viral evolution, HIV, statistical biology	Y
Olga Gonzalez, D.V.M.	Veterinary pathology at ABSL-2, 3, 4, infectious/natural diseases and aging of NHP	Y
Jack Dutton, D.V.M.	Veterinarian, ABSL-2, 3, 4, animal models of infectious disease, countermeasure assessment	N
Kathy Brasky, V.M.D.	Primary veterinarian, ABSL-2, 3, 4, animal models of infectious disease, countermeasure assessment, diverse NHP biology	Y
Jason Bowling, M.D.	Human infectious disease medicine, epidemiology, infection prevention	Y
John Choe, M.D.	Occupational health	N
Gregory Ippolito, Ph.D.	Immunology, antibody Repertoires, B-cell biology, vaccines and infectious diseases	Y

Quorum: was present 11/17 = 64.7 %

Other Individuals in Attendance: Erica Arreola and Winka Le Clec'h – recording the Institutional minutes.

Call to order: The IBC Chair called the meeting to order at 10:00 am

Conflicts of Interest: Request was made to members to self-identify if conflicts of interest arise and recuse as necessary.

Approval of Previous Minutes: Minutes from RDC/BSC July 2025 approved.

Update on Previous business: All revisions required from last meeting were made and approved.

Discussion: The IBC welcomes Dr. Gregory Ippolito as a new member. Dr. Ippolito brings several years of experience serving on the IBC at UT Austin. Some IBC members were not present due to mandatory FSAP training.

New Applications & Amendments for Review:

PI Name: Julie Ling

BSCRDC22-004.2– Increased AAV titers

Lay description, provided by PI: This amendment proposes an increase in Adeno-Associated Virus (AAV) titers and the use of smaller Cas gene-editing constructs. Purified AAV preparations are safe for humans and serve as effective tools for gene therapy. The long-term goal of the parent application is to develop a cure for HIV by excising the proviral genome from the host genome.

Agent characteristics: Adeno-associated virus (AAV).

Types of manipulations planned: The AAV vectors encode guide RNA sequences and Cas editing proteins designed to excise the HIV/SIV proviral genome from the host cell genome. These vectors will be employed in the NHP/SIV model, with AAV stocks provided by an external collaborator.

Sources of nucleic acids: Cas9, Cas12f, guide RNAs

Nature of sequences: Editing proteins and guide RNAs are used to excise HIV/SIV genomes from infected host cells.

Foreign gene(s) expressed: Cas9, Cas12f, guide RNAs.

Hosts and vectors to be used: Host: Rhesus Macaque. Vector: Adeno-associated virus (AAV).

Biosafety Level and containment: BSL-2.

PI and lab staff trained: The Ling laboratory and the veterinary staff have extensive experience and have already conducted similar studies.

Occupational Health Representative Review (if applicable)

No additional occupational health requirements were recommended at this time.

Risk Assessment and Discussion

Applicable section of guidelines: III-D-4a

The following will require clarification: None.

Motion: **Approval** | **11 Approve, 0 Against, 0 Abstain**

****

PI Name: P. Haldipur

IBC25-013– Leveraging cerebellar development research in non-human primates to enhance our understanding of the origins of cerebellar birth defects and tumors

Lay description, provided by PI: The cerebellum plays a critical role in movement and cognitive functions, and disruptions in its development can lead to serious congenital abnormalities. This study will use nonhuman primates (baboons), which are phylogenetically closer to humans, to better understand cerebellar development through histological and transcriptomic analyses.

Agent characteristics: BrdU/EdU

Types of manipulations planned: BrdU/EdU administered (100 mg/kg) to pregnant female baboons one hour prior to C-section, followed by collection of fetal tissues for histological and transcriptomic analyses.

Sources of nucleic acids: No recombinant/synthetic nucleic acids involved

Nature of sequences: NA

Foreign gene(s) expressed: NA

Hosts to be used: Baboons.

Biosafety Level and containment: ABSL-2.

PI and lab staff trained: All staff are experienced and trained in conducting baboon research.

Occupational Health Representative Review (if applicable)

No additional occupational health requirements were recommended at this time.

Risk Assessment and Discussion

Applicable section of guidelines: Not described.

The following will require clarification: Details are needed on where fetal tissues will be processed for histological, transcriptomic, and comparative analyses prior to shipment; potential maternal health impacts from BrdU/EdU administration (compound toxicity) and C-sections (effects on fertility and risk of endometriosis); and whether female baboons will return to the colony. Clarification is also requested regarding staff exposure risks (BrdU/EdU), training and animal handling, waste management, and environmental protection measures during and after procedures.

Motion: **A revised version needs to be recirculated before a vote is taken.**

****

Meeting adjourned at 10:25AM

Next IBC meeting:

9/18/2025 10:00 AM, Zoom